Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-23	US$11.08	+5.42%	257,823
26-06-22	US$10.51	-12.49%	538,020
26-06-18	US$12.01	-18.96%	380,694
26-06-17	US$14.82	-11.42%	198,315
26-06-16	US$16.73	-2.11%	157,403

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-23 EDT			5-day change	1st Jan Change
11.08 ^USD	+5.42%		-33.77%	-47.24%

05-08	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
25-10-31	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI

Market Cap	5.49B 4.82B 4.44B 4.16B 7.79B 520B 7.93B 53.36B 20.66B 255B 20.61B 20.17B 887B	P/E 2024	-10.2x	P/E 2025	-2,351x
Enterprise Value	5.49B 4.82B 4.44B 4.16B 7.79B 520B 7.92B 53.32B 20.64B 255B 20.59B 20.15B 886B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	11.64%	Yield 2024 *	-	Yield 2025	-

05-08	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
25-10-31	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
25-10-30	Regencell Bioscience Holdings Limited Auditor Raises 'Going Concern' Doubt	CI
25-09-21	Regencell Bioscience Holdings Limited(NasdaqCM:RGC) added to S&P Global BMI Index	CI
25-06-30	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2024	CI
25-06-30	Regencell Bioscience Holdings Limited Announces Board Changes, Effective June 30, 2025	CI
25-06-25	Top Premarket Gainers	MT
25-06-23	Top Premarket Decliners	MT
25-06-20	Top Premarket Decliners	MT
25-06-18	Top Premarket Decliners	MT
25-06-17	Top Premarket Gainers	MT
25-06-17	Regencell Bioscience Extends Gains Pre-Bell Tuesday Following 276% Surge Monday	MT
25-06-16	Top Premarket Gainers	MT

06-16	RGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE
06-16	RGC Holzer & Holzer, LLC Reminds Investors of the June 23, 2026 Lead Plaintiff Deadline in the Regencell Bioscience Holdings Limited Securities Class Action	NE
06-15	RGC Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE
06-11	RGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026	NE
06-10	RGC INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026	NE

Regencell Bioscience Holdings Limited Stock

Stocks

RGC

KYG7487R1002

Biotechnology & Medical Research

Valuation: Regencell Bioscience Holdings Limited

Chart: Regencell Bioscience Holdings Limited

Latest news : Regencell Bioscience Holdings Limited

Analysts' recommendations: Regencell Bioscience Holdings Limited

Press Releases: Regencell Bioscience Holdings Limited

News in other languages: Regencell Bioscience Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: Regencell Bioscience Holdings Limited

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

25-06-27	El milagro de las hierbas : esta acción sube un 20.000% en un año sin vender nada
22-02-17	La formule liquide expérimentale RGC-COV19TM de Regencell Bioscience a démontré son efficacité, chez ses patients recrutés, dans l'élimination des symptômes légers à modérés de la COVID-19 au cours d'une période de traitement de...
22-02-17	La formulazione liquida sperimentale RGC-COV19TM di Regencell Bioscience si dimostra efficace nell'eliminazione dei sintomi di COVID-19 da lievi a moderati nei pazienti arruolati nello studio di efficacia EARTH, in un periodo di trattamento di 6...
22-02-17	Flüssigprüfformel RGC-COV19TM von Regencell Bioscience zeigt Wirksamkeit bei den rekrutierten Patienten in der Wirksamkeitsstudie EARTH und behebt leichte bis mäßige COVID-19-Symptome innerhalb von 6 Tagen
22-02-17	Ensayo de eficacia EARTH: la fórmula líquida en investigación RGC-COV19TM de Regencell Bioscience demuestra eficacia en los pacientes inscritos al eliminar los síntomas leves o moderados de la COVID-19 en un período de tratamiento de seis días

1 day	+5.42%
1 week	-33.77%
Current month	-53.64%
1 month	-57.05%
3 months	-56.06%
6 months	-56.12%
Current year	-47.24%

1 week	10.15	14.85
1 month	10.15	27.5
Current year	10.15	69
1 year	9.39	69
3 years	0.08	83.6
5 years	0.08	83.6
10 years	0.08	83.6

Manager	Title	Age	Since
Yat-Gai Au CEO	Chief Executive Officer	54	2013-12-31
Wai Hong Chung COO	Chief Operating Officer	49	2021-07-31
Yat-Pui Au PRN	Corporate Officer/Principal	52	2023-01-31

Director	Title	Age	Since
Wing Yan Lo BRD	Director/Board Member	65	2021-12-12
Wai Hong Chung BRD	Director/Board Member	49	2023-12-27
Yee Wah Hui BRD	Director/Board Member	54	2021-06-30

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-26	Yee Wah Hui	Issuer sale	Director	-19,000	0.0038%
05-26	Wing Yan Lo	Issuer sale	Director	-70,600	0.0143%
03-17	Yat-Gai Au	Other	Chief Executive Officer	581,514	0.1176%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+5.42%	-33.77%	-53.25%	+1,691.72%	5.21B
LONZA GROUP AG	+2.96%	+4.21%	-8.16%	-2.76%	43.24B
REVOLUTION MEDICINES, INC.	+2.23%	+8.26%	+323.35%	+564.22%	35.25B
BEONE MEDICINES AG	+1.59%	+4.63%	+7.23%	+54.02%	30.22B
IQVIA HOLDINGS INC.	+2.07%	-4.40%	+10.38%	-19.99%	28.01B
CELLTRION, INC.	-4.75%	-8.29%	+3.90%	+13.88%	24.08B
ASCENDIS PHARMA A/S	+4.64%	+3.20%	-	-	14.16B
MEDPACE HOLDINGS, INC.	+3.91%	+2.57%	+53.41%	+111.95%	13.01B
EUROFINS SCIENTIFIC SE	+2.77%	+4.02%	+9.61%	+15.31%	12.7B
IONIS PHARMACEUTICALS, INC.	+0.13%	+3.97%	+101.73%	+91.70%	12.54B
Average	+2.10%	-4.56%	+49.80%	+280.01%	21.84B
Weighted average by Cap.	+1.74%	-1.62%	+65.92%	+160.53%

	2024	2025
Net sales	-	-
Net income	-4.3M -3.78M -3.48M -3.26M -6.11M -408M -6.21M -41.81M -16.19M -200M -16.15M -15.8M -695M	-3.58M -3.15M -2.9M -2.72M -5.09M -340M -5.17M -34.84M -13.49M -167M -13.46M -13.17M -579M
Net Debt	-7.88M -6.92M -6.38M -5.97M -11.18M -746M -11.37M -76.55M -29.63M -366M -29.56M -28.93M -1.27B	-4.35M -3.82M -3.52M -3.3M -6.18M -412M -6.28M -42.31M -16.38M -202M -16.34M -15.99M -703M